摘要:
Cyclic compounds of the general formula wherein one of R' and R 2 is hydrogen and the other is hydrogen or hydroxy or R' and R 2 taken together are a protected oxo group; R 3 is hydrogen, hydroxy or acyloxy; R' is lower alkyl, esterified carboxy or a group of the formula -C(R 5 , R 6 ) -CH 2 -X; R' and R'taken together are oxo or protected oxo; X is hydrogen, hydroxy, acyloxy or -(CH 2 ) n -OY; Y is hydrogen, alkyl or acyl and n is 1 or 2; with the proviso that one of R 1 and R 2 is hydrogen and the other is hydroxy or R 1 and R 2 taken together are protected oxo when R' is acetoxy and R' is acetyl; processes for the preparation thereof and intermediates in these processes.
摘要翻译:其中R 1和R 2之一为氢,另一个为氢或羟基或R 1和R 2一起为保护的氧代基; R 3是氢,羟基或酰氧基; R 4是低级烷基,酯化羧基或式-C(R 5,R 6)-CH 2 -X的基团; R 5和R 6一起是氧代或受保护的氧代; X是氢,羟基,酰氧基或 - (CH 2)n -OY; Y是氢,烷基或酰基,n是1或2; 条件是R 1和R 2之一是氢,另一个是羟基或R 1和R 2一起被保护为氧代,当R 3是乙酰氧基且R 4是 乙酰基;其制备方法和这些方法中的中间体。
摘要:
Esters of 4,5-disubstituted-oxy-2-rnethyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids were prepared chemically and/or enzymatically. Depending upon the ester, improved melanocyte cytotoxicity was achieved. Improved cytotoxicity characteristics are consistent with ester analogs being more physiologically compatible and less irritating to skin than their corresponding acids.
摘要:
Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Tip-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.
摘要:
Use of 1,3,4,6-tetrahydroxy-helianthrone and substituted derivative thereof as photoactivators for the photodynamic therapy of tumors. There are also provided novel substituted derivatives of 1,2,4,6-tetrahydroxy-helianthrone.
摘要:
Disubstituted lavendustin A analogs that are PTK inhibitors having antiproliferative activity are described. Preferred compounds of the present invention, without limitation, satisfy either Formula (1) or Formula (2). Currently preferred compounds, based on in vivo biological activity, are 4'-adamantylbenzoate-1'-N-1,4-dihydroxybenzylamine and 4'-adamantylmethylbenzoate-1'-N-1,4-dihydroxybenzylamine. The present invention also provides pharmaceutical compositions comprising effective amounts of disubstituted lavendustin A analogs. Such compositions also may comprise other active ingredients, other materials conventionally used in the formulation of pharmaceutical compositions, and mixtures thereof. The compounds and compositions of the present invention can be used for treating subjects to, for example, inhibit the proliferation of living cells in the treatment of proliferative diseases.
摘要:
Le procédé consiste en l'isomerisation à l'aide d'un agent acide d'un époxy-ester de formule
dans laquelle R sert à désigner un radical alkyle inférieur C₁-C 6, linéaire ou ramifié, et la ligne ondulée définit une liaison C-C de configuration cis ou trans.
摘要:
Es wird ein Verfahren zur Herstellung von 4-O-Alkyl-rhodomycinen der Formel I worin R¹ H, C₁-C₄-Alkyl oder eine Acylschutzgruppe, R² OH, COOCH₃, O-Si(C₁-C₄-Alkyl)₃ oder eine O-Acylschutzgruppe, wobei Acyl Acetyl, Mono-, Di- oder Trihalogenacetyl mit Fluor oder Chlor als Halogen, Benzoyl oder p-Nitrobenzoyl bedeutet, R³ C₁-C₄-Alkyl, R⁴ H oder R⁴ und R⁵ zusammen eine Tetraisopropyldisiloxan-1,3-diyl-Schutzgruppe, R⁵ H oder einen Glycosylrest der Formel II, in der R⁶ OH, Acetyloxy, NHCOCF₃, NH₂, eine Mono- oder Di-C₁-C₄-alkylaminogruppe oder eine 4-Morpholinyl-Gruppe, R⁷ H, OH, eine Acetyloxy-, Trifluoroacetyloxy- oder p-Nitrobenzoyloxygruppe sind, bedeuten, und deren Verwendung zur Herstellung von 7-O-Glycosyl-rhodomycinen, die aufgrund ihrer zytostatischen Wirksamkeit für die Behandlung von Krebserkrankungen geeignet sind, beschrieben.